Dermata Therapeutics Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
9
- Stock Symbol
-
DRMA
- Share Price
-
$0.51
- (As of Friday Closing)
Dermata Therapeutics General Information
Description
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.
Contact Information
Website
www.dermatarx.comCorporate Office
- 3525 Del Mar Heights Road
- Suite 322
- San Diego, CA 92130
- United States
Corporate Office
- 3525 Del Mar Heights Road
- Suite 322
- San Diego, CA 92130
- United States
Dermata Therapeutics Timeline
Dermata Therapeutics Stock Performance
As of 20-Nov-2026, Dermata Therapeutics’s stock price is $0.51. Its current market cap is $2.51M with 4.93M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.51 | $0.53 | $0.50 - $4.66 | $2.51M | 4.93M | 2.75M | -$3.28 |
Dermata Therapeutics Financials Summary
As of 30-Sep-2026, Dermata Therapeutics has a trailing 12-month revenue of $74.1K.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,038 | 2,755 | (3,389) | (4,473) |
| Revenue | 74 | 0 | 0 | 0 |
| EBITDA | (9,699) | (7,774) | (12,513) | (8,042) |
| Net Income | (9,498) | (7,559) | (12,287) | (7,795) |
| Total Assets | 6,635 | 7,864 | 3,534 | 7,979 |
| Total Debt | 0 | 0 | 0 | 0 |
Dermata Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Dermata Therapeutics Comparisons
Industry
Financing
Details
Dermata Therapeutics Competitors (26)
One of Dermata Therapeutics’s 26 competitors is Zylo Therapeutics, a Venture Capital-Backed company based in Greenville, SC.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Zylo Therapeutics | Venture Capital-Backed | Greenville, SC | ||||
| Spear Pharmaceuticals | Formerly PE-Backed | Randolph, NJ | ||||
| Nymox Pharmaceutical | Corporation | Saint Laurent, Canada | ||||
| Crescita Therapeutics | Corporation | Laval, Canada | ||||
| Aquapharm Biodiscovery | Formerly VC-backed | Oban, United Kingdom |
Dermata Therapeutics Patents
Dermata Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024151612-A1 | Compositions for inducing immune responses | Inactive | 13-Jan-2023 | ||
| AU-2021394765-A1 | Compositions for the treatment of skin conditions | Pending | 09-Dec-2020 | ||
| CA-3204909-A1 | Compositions for the treatment of skin conditions | Pending | 09-Dec-2020 | ||
| EP-4267163-A1 | Compositions for the treatment of skin conditions | Pending | 09-Dec-2020 | ||
| EP-4267163-A4 | Compositions for the treatment of skin conditions | Pending | 09-Dec-2020 | A61K8/987 |
Dermata Therapeutics Signals
Dermata Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Dermata Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Household Products
Industry
Rank
Percentile
Personal Products
Subindustry
Rank
Percentile
Dermata Therapeutics FAQs
-
When was Dermata Therapeutics founded?
Dermata Therapeutics was founded in 2014.
-
Where is Dermata Therapeutics headquartered?
Dermata Therapeutics is headquartered in San Diego, CA.
-
What is the size of Dermata Therapeutics?
Dermata Therapeutics has 9 total employees.
-
What industry is Dermata Therapeutics in?
Dermata Therapeutics’s primary industry is Other Commercial Products.
-
Is Dermata Therapeutics a private or public company?
Dermata Therapeutics is a Public company.
-
What is Dermata Therapeutics’s stock symbol?
The ticker symbol for Dermata Therapeutics is DRMA.
-
What is the current stock price of Dermata Therapeutics?
As of 20-Nov-2026 the stock price of Dermata Therapeutics is $0.51.
-
What is the current market cap of Dermata Therapeutics?
The current market capitalization of Dermata Therapeutics is $2.51M.
-
What is Dermata Therapeutics’s current revenue?
The trailing twelve month revenue for Dermata Therapeutics is $74.1K.
-
Who are Dermata Therapeutics’s competitors?
Zylo Therapeutics, Spear Pharmaceuticals, Nymox Pharmaceutical, Crescita Therapeutics, and Aquapharm Biodiscovery are some of the 26 competitors of Dermata Therapeutics.
-
What is Dermata Therapeutics’s annual earnings per share (EPS)?
Dermata Therapeutics’s EPS for 12 months was -$3.28.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process